Abstract: A method of treating symptoms of benign prostatic hypertrophy and a method of treating lower urinary tract symptoms, are disclosed. The method includes administering to a mammal about 1 to about 20 milligrams of an agent that inhibits cyclic guanosine 3,5-monophosphate specific phosphodiesterase type 5.
Type:
Application
Filed:
October 10, 2006
Publication date:
April 26, 2007
Applicant:
LILLY ICOS LLC
Inventors:
Bela Denes, Kenneth Ferguson, John Whitaker
Abstract: Compounds that inhibit DNA-dependent protein kinase, compositions comprising the compounds, methods to inhibit the DNA-PK biological activity, methods to sensitize cells the agents that cause DNA lesions, and methods to potentiate cancer treatment are disclosed.
Type:
Grant
Filed:
August 28, 2001
Date of Patent:
February 20, 2007
Assignee:
ICOS Corporation
Inventors:
James Halbrook, Edward A. Kesicki, Laurence E. Burgess, Stephen T. Schlachter, Charles T. Eary, Justin G. Schiro, Hongmei Huang, Michael Evans, Yongxin Han
Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
Type:
Grant
Filed:
November 7, 2005
Date of Patent:
February 13, 2007
Assignee:
ICOS Corporation
Inventors:
Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Edward A. Kesicki, Amy Oliver, Laurence Edward Burgess, John Joseph Gaudino, Zachary S. Jones, Bradley J. Newhouse, Stephen T. Schlachter
Abstract: Methods to inhibit inflammation and macrophage infiltration following spinal cord injury are disclosed along with methods to modulate TNF? release from cells expressing ?d are disclosed.
Abstract: The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding, cGMP-specific phosphodiesterase designated cGB-PDE. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.
Type:
Application
Filed:
December 21, 2005
Publication date:
September 28, 2006
Applicants:
ICOS CORPORATION
Inventors:
Joseph Beavo, Jackie Corbin, Kenneth Ferguson, Sharron Francis, Ann Kadlecek, Kate Loughney, Linda McAllister-Lucas, William Sonnenburg, Melissa Thomas
Abstract: Pyrazole compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
Type:
Grant
Filed:
April 18, 2003
Date of Patent:
August 8, 2006
Assignee:
ICOS Corporation
Inventors:
Timothy J. Martins, Kerry W. Fowler, Carmen C. Hertel, Amy Oliver
Abstract: Aryl- and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are disclosed.
Type:
Grant
Filed:
March 1, 2002
Date of Patent:
June 27, 2006
Assignee:
ICOS Corporation
Inventors:
Kathleen S. Keegan, Edward A. Kesicki, John Joseph Gaudino, Adam Wade Cook, Scott Douglas Cowen, Laurence Edward Burgess
Abstract: The present invention relates to methods for making multimeric proteins comprising fusion of two or more cells expressing a single subunit of the multimeric protein to generate a single hybrid cell expressing the fully assembled multimeric protein.
Abstract: The invention relates generally to methods for treating and/or preventing aberrant proliferation of hematopoietic cells. More particularly, the invention relates to methods for treating and/or preventing aberrant proliferation of hematopoietic cells comprising selectively inhibiting phosphoinositide 3-kinase delta (PI3K?) activity in hematopoietic cells. The methods may be used to treat any indication involving aberrant proliferation of hematopoietic cells.
Type:
Application
Filed:
May 25, 2005
Publication date:
May 18, 2006
Applicant:
ICOS CORPORATION
Inventors:
Didier Bouscary, Joel Hayflick, Catherine Lacombe, Patrick Mayeux
Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
Type:
Application
Filed:
November 7, 2005
Publication date:
April 6, 2006
Applicant:
ICOS CORPORATION
Inventors:
Timothy Martins, Kerry Fowler, Joshua Odingo, Edward Kesicki, Amy Oliver, Laurence Burgess, John Gaudino, Zachary Jones, Bradley Newhouse, Stephen Schlachter
Abstract: The present invention provides purified and isolated polynucleotide sequences encoding a novel macrophage-derived C-C chemokine designated “Macrophage Derived Chemokine” (MDC), and polypeptide fragments and analogs thereof. Also provided are materials and methods for the recombinant or synthetic production of the chemokine, fragments, and analogs; and purified and isolated chemokine protein, and polypeptide fragments and analogs thereof. Also provided are antibodies reactive with the chemokine and methods of making and using all of the foregoing. Also provided are assays for identifying modulators of MDC chemokine activity.
Type:
Application
Filed:
October 28, 2005
Publication date:
March 16, 2006
Applicant:
ICOS CORPORATION
Inventors:
Patrick Gray, David Chantry, Michael Deeley, Carol Raport, Ronald Godiska
Abstract: The invention provides a novel human poly(ADP-ribose) polymerase (hPARP2) polypeptides, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, and host cells transformed with the expression constructs. Also provided are methods for producing the hPARP2 polypeptides, antibodies that are immunoreactive with the hPARP2 polypeptides. In addition, there are provided methods for identifying specific binding partners of hPARP2, and more particularly methods for identifying binding partners that modulate biological activity of hPARP2. Methods of modulating biological activity of hPARP2 in vitro and in vivo are also provided.
Type:
Grant
Filed:
February 19, 2003
Date of Patent:
January 24, 2006
Assignee:
ICOS Corporation
Inventors:
Erik Christenson, Anthony J. DeMaggio, Phyllis S. Goldman, David L. McElligott
Abstract: An inspection system optically examines the surfaces of objects to detect surface errors. The system scans image strips and, consequently, a given surface rapidly and with sufficient resolution using a linescan camera and an upstream microscope by aligning the captured lines.
Abstract: Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3K? plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3K5, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity. Methods of using PI3K? inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3K? inhibitory compounds to inhibit PI3K?-mediated processes in vitro and in vivo.
Type:
Application
Filed:
April 20, 2005
Publication date:
November 24, 2005
Applicant:
ICOS CORPORATION
Inventors:
Chanchal Sadhu, Ken Dick, Jennifer Treiberg, C. Sowell, Edward Kesicki, Amy Oliver
Abstract: The present invention provides polynucleotides that encode the chemokine receptors 88-2B or 88C and materials and methods for the recombinant production of these two chemokine receptors. Also provided are assays utilizing the polynucleotides which facilitate the identification of ligands and modulators of the chemokine receptors. Receptor fragments, ligands, modulators, and antibodies are useful in the detection and treatment of disease states associated with the chemokine receptors such as atherosclerosis, rheumatoid arthritis, tumor growth suppression, asthma, viral infection, AIDS, and other inflammatory conditions.
Type:
Application
Filed:
February 28, 2005
Publication date:
November 24, 2005
Applicant:
ICOS CORPORATION
Inventors:
Patrick Gray, Vicki Schweickart, Carol Raport
Abstract: Aryl- and heteroaryl-substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are disclosed.
Type:
Application
Filed:
April 27, 2005
Publication date:
November 3, 2005
Applicant:
ICOS CORPORATION
Inventors:
Kathleen Keegan, Edward Kesicki, John Gaudino, Adam Cook, Scott Cowen, Laurence Burgess
Abstract: The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C—C chemokine designated Macrophage Derived Chemokine (MDC), and polypeptide analogs thereof. Also provided are materials and methods for the recombinant production of the chemokine, and purified and isolated chemokine protein, and polypeptide analogs thereof. Also provided are antibodies reactive with the chemokine and methods of making and using all of the foregoing.
Type:
Application
Filed:
April 6, 2004
Publication date:
October 27, 2005
Applicant:
ICOS CORPORATION
Inventors:
Patrick Gray, David Chantry, Michael Deeley
Abstract: Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K?) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3K? plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3K?, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3K? activity, including compounds that selectively inhibit PI3K? activity. Methods of using PI3K? inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3K? inhibitory compounds to inhibit PI3K?-mediated processes in vitro and in vivo.
Type:
Grant
Filed:
October 30, 2003
Date of Patent:
September 27, 2005
Assignee:
ICOS Corporation
Inventors:
Chanchal Sadhu, Ken Dick, Jennifer Treiberg, C. Gregory Sowell, Edward A. Kesicki, Amy Oliver
Abstract: The present invention relates to highly selective phosphodieterase (PDE) enzyme inhibitors and to their use in pharmaceutical articles of manufacture. In particular, the present invention relates to potent inhibitors of cyclic guanosine 3?,5?-monophosphate specific phosphodiesterase type 5 (PDE5) that when incorporated into a pharmaceutical product at about 1 to about 20 mg unit dosage are useful for the treatment of sexual dysfunction.
Type:
Grant
Filed:
April 26, 2000
Date of Patent:
September 13, 2005
Assignee:
Lilly ICOS LLC.
Inventors:
William Ernest Pullman, John Steven Whitaker
Abstract: The present invention provides compounds comprising a bicyclic aryl moiety, such as 2H-phthalazin-1-one or derivatives thereof, compositions comprising the same, and methods for producing and using the same. In particular, the present invention provides compounds of the formula: or a pharmaceutically acceptable salt, a hydrate, a solvate, or a prodrug thereof; where Q1, Q2 and Y are those defined herein.
Type:
Grant
Filed:
August 15, 2002
Date of Patent:
August 2, 2005
Assignees:
ICOS Corporation, Deltagen Research Labs, LLC
Inventors:
Graham Beaton, Wilna J. Moree, Jaimie K. Rueter, Russell S. Dahl, David L. McElligott, Phyllis Goldman, Anthony J. Demaggio, Erik Christenson, Dan Herendeen, Kerry W. Fowler, Danwen Huang, Jaimie E. Bertino, Lisa H. Bourdon, David J. Fairfax, Qin Jiang, Helge A. Reisch, Ren Hua Song, Pavel E. Zhichkin